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Abstract
Background: The present study compares antiepileptic drugs and aromatase (CYP19) inhibitors for chemical and
structural similarity. Human aromatase is well known as an important pharmacological target in anti-breast cancer
therapy, but recent research demonstrates its role in epileptic seizures, as well. The current antiepileptic treatment
methods cause severe side effects that endanger patient health and often preclude continued use. As a result, less
toxic and more tolerable antiepileptic drugs (AEDs) are needed, especially since every individual responds
differently to given treatment options.
Methods: Through a pharmacophore search, this study shows that a model previously designed to search for new
classes of aromatase inhibitors is able to identify antiepileptic drugs from the set of drugs approved by the Food
and Drug Administration. Chemical and structural similarity analyses were performed using five potent AIs, and
these studies returned a set of AEDs that the model identifies as hits.
Results: The pharmacophore model returned 73% (19 out of 26) of the drugs used specifically to treat epilepsy
and approximately 82% (51 out of 62) of the compounds with anticonvulsant properties. Therefore, this study
supports the possibility of identifying AEDs with a pharmacophore model that had originally been designed to
identify new classes of aromatase inhibitors. Potential candidates for anticonvulsant therapy identified in this
manner are also reported. Additionally, the chemical and structural similarity between antiepileptic compounds and
aromatase inhibitors is proved using similarity analyses.
Conclusions: This study demonstrates that a pharmacophore search using a model based on aromatase inhibition
and the enzyme’s structural features can be used to screen for new candidates for antiepileptic therapy. In fact,
potent aromatase inhibitors and current antiepileptic compounds display significant - over 70% - chemical and
structural similarity, and the similarity analyses performed propose a number of antiepileptic compounds with high
potential for aromatase inhibition.
Background
The need to discover and develop new antiepileptic drugs
(AEDs) is clear. The adverse side effects of the existent
therapies - from cognitive impairment [1] to depression,
anorexia, somnolence [2], and even birth defects [3] -
have long been reported. Even the newer anticonvulsant
medications have offered little relief [1,2]. In fact, harmful
side effects seem to be the most significant factor in the
approximately 35% long-term or 3-year retention rate for
all new AEDs [1]. As a result, less toxic and more toler-
able AEDs are needed, especially since every individual
responds slightly differently to given treatment options.
A greater number of less harmful AEDs could serve as
helpful alternatives for those who do not respond well to
current treatments.
One potential avenue for the design of more tolerable
AEDs exists in the subset of small molecules that inhibit
the enzyme aromatase (CYP19), a cytochrome P450
enzyme that catalyzes the conversion of androgens into
estrogens. In fact, aminoglutethimide, a drug that had
been originally pursued for anticonvulsant therapy, even-
tually became the first-generation aromatase inhibitor [4].
Interestingly, several antiepileptic drugs - like lamotrigine,
oxcarbazepine (also known as oxacarbazepine), tiagabine,
phenobarbital, phenytoin, ethosuximide, (ethosusuximide),
and valproic acid (valproate) - are known to inhibit
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[5]. In fact, some aromatase inhibitors (AIs) - like letro-
zole, for example, which has been approved for the treat-
ment of breast cancer by the Food and Drug
Administration (FDA) [6] - have been clinically successful
in treating epilepsy in men [7].
Aromatase inhibitors have been especially useful for
treating male patients with sexual or reproductive dysfunc-
tion in addition to epilepsy [7]. They have also been pre-
scribed clinically when the current antiepileptic treatment
options lead to side effects severe enough to preclude con-
tinued use and even when AEDs proved ineffective in con-
trolling epilepsy [8]. Sexual or reproductive abnormalities
often seen in epileptic males are typically attributed to the
fact that estrogens suppress sexual interest and function in
males [9]. Estradiol in particular, the most potent estrogen
in the human body [10], is found at elevated levels in men
with epilepsy [11]. In fact, many clinical studies indicate
that a statistically significant and relatively high percentage
of individuals with epilepsy, whether male or female, also
display sexual dysfunction [3,7-9,11], reproductive dys-
function [8,9,11], and hormonal or endocrine abnormal-
ities [9,11] as would be expected from high estrogen levels.
Among women, the relationship between epilepsy and
estrogen imbalance is especially striking. For example, it
has been shown that around 56.5% of women with ame-
norrhea or anovulatory cycles have electroencephalogra-
phy (EEG) abnormalities [9]. Seizure frequency can also be
associated with perimenarche [12,13] menarche [9,12],
menstruation [3,9,12-14], pregnancy [9,12], perimeno-
pause [3,12,13], and menopause [3,9,12,13]. Catamenial
epilepsy, a form of epilepsy in which the periodicity of sei-
zure exacerbation corresponds closely with the menstrual
cycle, is thought to affect from 30% to as much as 70% of
epileptic females [3,9,12-14]. This type of epilepsy has
been found to exist in three distinct patterns [12-14], and
is thought to occur due to the surge of estrogen and with-
drawal of progesterone at ovulation [3]. However, the peri-
odicity of seizures is common in both genders [14].
Additionally, it has long been established that estrogens
are epileptogenic [9] and have proconvulsive effects [12] in
the human body. This is due to the ability of estrogens to
lower the seizure threshold [9,14], to increase seizure dis-
charges [9,14], and to increase neural membrane excitabil-
ity [12-14]. However, there have also been some studies
that hint at the potential anticonvulsant role of estrogens
[13] and this highlights the complex role of sex hormones
in the body and the complex etiology of epilepsy itself.
The conclusiveness of such studies could indeed be
clouded by other factors, especially since epileptic seizures
in general are known to depend on many factors other
than sex steroids.
For example, high progesterone levels, even during
periods of relatively high estrogen levels, could still
result in the antiepileptic effects witnessed in some
patients, especially since seizure frequency correlates in
a statistically significant manner with the serum estra-
diol:progesterone ratio [9]. In addition, it has been pre-
viously proposed that perhaps the different effects of
estradiol and other estrogens on epileptic tissue actually
depend on their final local concentrations [15]. The pre-
vious argument is further supported by the fact that
estrogens could act as substrates for aromatase (a better
terminology could be probably “false substrates”). Their
reactions generate catechol estrogen, 2-hydroxyestrogen,
and 6-hydroxyestrogen that may have critical roles in
the induction or promotion of estrogen-responsive
malignancies. Because of this, both androgens and estro-
gens act as competitive inhibitors of aromatase and deri-
vatives of both androgens and estrogens have been
tested as AIs [16].
All in all, however, the existence of a relationship
between estrogen biosynthesis and epilepsy is unmistak-
able, and scientific evidence exists to prove that all forms
of epilepsy may indeed have this common origin [17].
Regardless, the set of current antiepileptic drugs and the
set of known aromatase inhibitors certainly have several, if
not many, compounds in common. Similarly, screening
for potential AIs could lead to the identification of poten-
tial AEDs, as well. The focus of this study, therefore, is to
demonstrate this and to further analyze the common
features among AIs and AEDs in an effort to prove their
chemical and structural similarity.
Methods
Virtual screening
A previously generated pharmacophore model [18] is
shown in Figure 1. To generate this model, a Training Set
[18] of the 20 most potent, yet structurally-diverse aroma-
tase inhibitors known and presented in the literature was
created. These compounds were used to generate the
ligand-based (LB) pharmacophore model on Molecular
Operating Environment (MOE) [19]. The recently deter-
mined aromatase active site crystal structure (PDB code:
E3QM) [20] was used to generate the structure-based (SB)
pharmacophore model on LigandScout [21]. The SB model
was based on the interactions that define aromatase inhibi-
tion, such as hydrophobic interactions, hydrogen bonding,
and electrostatic interactions. The LB and SB models were
merged to create the Merged Model with a root mean
squared deviation (RMSD) value of 0.11 Å. All three mod-
els - the LB, SB, and Merged - were analyzed computation-
ally, and the Merged Model was found superior to the
original models by combining the strengths of both [18].
The Merged Model [18] was used to screen the set of
FDA-approved drugs as provided by the DrugBank [22,23].
The “approved” set of DrugBank molecules was down-
loaded as an sdf file, and each compound was converted
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(MVD) [24]. A database file was created using the Molecu-
lar Operating Environment (MOE) [19] by importing every
mol file from the “approved” set of DrugBank molecules.
The compounds with molecular weight lower than
550 were screened with the Merged Model, which had
been originally designed to screen for new classes of
aromatase inhibitors [18]. This was accomplished by
generating conformations for each “approved” drug and
by and analyzing these for potential matches with the
Merged Model through the conformation import func-
tion of the pharmacophore search function on MOE
[19]. The hits related to epilepsy and seizure therapy
were isolated by their DrugBank identification numbers.
Separately, conformations of every compound in the
set of aromatase inhibitors previously used to create and
to validate the pharmacophore model were generated
through the conformation import feature of the pharma-
cophore search function on MOE [19]. For each com-
pound, the conformation with the lowest root mean
square deviation (RMSD) from the Merged pharmaco-
phore model [18] was taken as the “ideal” conformation
for that specific compound.
The “ideal” conformations - one for each of the AIs -
were ranked according to RMSD. The five “ideal” con-
formations with the lowest RMSD values corresponded
to five individual AIs, which will hereafter be referred to
as the “top five AIs.” Thus, the top five AIs were those
capable of adopting a conformation with an RMSD
value among the five lowest RMSD values from the
Merged pharmacophore model. The top five AIs are
shown in Additional file 1: Table S1.
The chemical fingerprints of the top five AIs and of
the epilepsy-related hits were then calculated with the
fingerprints Typed Graph Triangles (TGT) [25] and
EigenSpectrum Shape (EShape3D) [26]. The TGT fin-
gerprint encodes three-point pharmacophores from two-
dimensional structures of the compounds. To each
atom, it assigns a given molecule type - donor, acceptor,
polar, anion, cation, or hydrophobe, - and all triplets are
coded as features using three graph distances (bond
count) and three atom types in each triplet. In contrast,
ESshape3D aims at rapidly determining the shape simi-
larity of molecules. The ESshape3D fingerprint starts by
calculating a matrix with the Euclidean distances
between all heavy atoms in molecule to thereafter form
a spectrum characteristic of its shape with the matrix’s
eigenvalues. This spectrum is then encoded as a finger-
print, and the similarity score is calculated as the inverse
of the distance between the corresponding fingerprints.
Therefore, the TGT and EShape3D fingerprint types
were chosen based on the important characteristics -
chemical features and shape of the molecule, respec-
tively - that they represent because these are crucial for
the especially substrate-specific binding pocket active
site of the aromatase enzyme [18,19]. The similarity
metric used with TGT was Tanimoto Coefficient; with
EShape3D, it was Inverse Distance. The threshold at
which top five AIs are found similar to the epilepsy-
related hits was determined by successively adjusting the
overlap value.
Ingenuity Pathway Analysis (IPA)
Pathways analysis is a method that allows the visualiza-
tion of biological pathways and that provides a greater
understanding of diseases [27]. IPA consists of an exten-
sive repository of biological and chemical knowledge,
offering the researcher access to the most current
Acc2 
Acc 
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Figure 1 Three-dimensional representation of the Merged pharmacophore model generated in previous work[18]. Two hydrophobic
groups (yellow spheres), two hydrogen-bond acceptors (red spheres), and 11 excluded volumes (gray spheres) are shown.
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families, normal cellular and disease processes, and sig-
naling and metabolic pathways. The software allows one
to search for information on genes and chemicals, their
impact on diseases and cellular processes, and their role
in signaling and metabolic pathways. One major pro-
blem that drug developers face is that many drugs share
similar targets, as evidenced by phenotypic side-effects
similarities [28], or that a given drug may be capable of
targeting more than one protein. This is generally due
to two effects: (1) target promiscuity (i.e. the promiscu-
ity of the proteins themselves, their involvement in mul-
tiple functions, and their structural similarities, as well
as their involvement in complex networks of interac-
tions that simultaneously couple several cellular path-
ways), and (2) chemical similarities of many small
molecule inhibitors as evidenced by the recent global
mapping of the pharmacological space [29].
Results
T h eA I st h a tw e r ef o u n dt ob ei nt h et o pf i v ew e r ea l s o
experimentally found to be of high potency for inhibiting
aromatase in vitro relative to other known AIs. The inhi-
bitory half-maximal concentration (IC50)v a l u e so ft h e
top five AIs are shown in Additional file 1: Table S1.
Interestingly, four out of five had been among the 20
most potent AIs that were used to generate the pharma-
cophore model. However, the final pharmacophore
model with which the DrugBank database was screened
for this study had been generated from both this set of 20
most potent AIs and from the active site crystal structure
of the aromatase enzyme. Thus, these AIs represent
those among the 20 most potent that closely match the
chemical features and shape necessary for inhibition as
dictated by the active site structure, as well, further
demonstrating the essential role of the structure-based
pharmacophore model [18].
The fifth AI - liarozole, - although inhibitory in the
nanomolar range [30,31], had been deemed too similar
in chemical structure to vorozole [30-32], one of the 20
most potent AIs in the Training Set used to generate
the Merged Model; therefore, it was used to test the
model rather than to generate it [18]. Regardless, it is
identified as one of the AIs with the lowest RMSD from
the pharmacophore model, as is vorozole. Vorozole is
an AI currently being tested in Phase IV clinical trials
[32], and anastrozole is already an FDA-approved drug
[6] for treating breast cancer [4,6]. It is noted that ami-
noglutethimide, a first generation AI with severe toxic
side effects that had originally been pursued as anticon-
vulsant therapy [4], was not found among the top five.
Therefore, the top five AIs represent a set of com-
pounds that are not biased toward any AEDs.
The Merged pharmacophore model [18] was found to
identify many of the antiepileptic drugs contained in the
FDA-approved subset of drugs in the DrugBank [22,23].
Among the 26 drugs in the FDA-Approved database of
the DrugBank [22,23] specifically used to treat epilepsy,
the Merged Model hit 19 (73%). Out of the 62 com-
pounds listed as having anticonvulsant properties, a sub-
set of which were the AEDs used for epilepsy therapy,
the Merged Model returned 51 (82%). Additionally, the
Merged Model [18] hit seven out of seven compounds
that had been proven to have both anticonvulsant and
aromatase-inhibiting affects [5] (100%). These com-
pounds are shown in Additional file 2: Table S2. Results
of the similarity analyses that were conducted on the
entire set of AEDs with the top five AIs are shown in
Additional file 3: Table S3.
To understand the toxicity of the FDA approved AEDs,
a pathway analysis with IPA was performed to identify
the targets that are being affected by these molecules.
The IPA analysis was applied to current AEDs as well as
to the hits that resulted from the pharmacophore screen-
ing. As illustrated in Figures 2 and 3, with this program,
targets are represented as geometrical shapes (i.e. circle,
square, ellipse, etc.), and arrows connecting the molecule
of interest to different targets represent a biological rela-
tionship that is supported by at least one published refer-
ence or by the IPA knowledge base. These maps can be
multidimensional and provide information about cyto-
kines, growth factors, small molecule drugs or toxicants,
enzymes, G-protein coupled receptors, ion channels,
kinases, ligand-dependent nuclear receptors, peptidases,
phosphatases, transcription regulators, translation regula-
tors, transmembrane regulators, transporters, microRNA,
complexes, and other important molecules.
Discussion
A key result of this study is the identification of AEDs that
the similarity search methods used - TGT and EShape3D
- identify to be similar to a given top five AI by at least an
overlap value of 70%. Additional file 3: Table S3 shows
the results of these similarity analyses, in which the set of
antiepileptic drugs were analyzed for similarity with the
top five AIs according to fingerprint methods TGT and
EShape3D. If an AED was identified to be similar with a
top five AI by at least one of the fingerprint methods, its
DrugBank identification number was written in Additional
file 3: Table S3 corresponding to the top five AI with
which it was found similar and to the overlap values - 70%
or higher - at which it was found similar.
Among these compounds, those that were found
similar to one of the top five AIs at an overlap value
of at least 70% by both fingerprint methods were
reported in bolded text in Additional file 3: Table S3,
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tional file 4: Table S4. These compounds are, there-
fore, considered to have high probability to inhibit the
human aromatase enzyme because they have been
identified as similar to a top five AI in terms of
chemical features and also according to compound
shape. In this manner, the similarity search analysis
very clearly proposes five AEDs with potential for aro-
matase inhibition. These five AEDs have not been
assayed for aromatase inhibition according to the
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Phenytoin 
(DB #252) 
Valproic Acid 
(DB #313) 
Phenobarbital 
(DB #1174) 
Tiagabine 
(DB #906) 
Lamotrigine 
(DB #555)
 
Ethosuximide 
(DB #593) 
Figure 2 Diagrams depicting interactions between six of the seven aromatase-inhibiting AEDs, oxcarbazepine (DB #776) not included,
since information about its interactions was unavailable. Specific molecule types are represented as: cytokines (square), growth factors
(dotted square), small molecule drugs or toxicants (oval), enzymes (vertical diamond), G-protein coupled receptors (vertical rectangle), ion
channels (dotted vertical rectangle), kinases (inverted traingle), ligand-dependent nuclear receptors (rectangle), peptidases (horizontal diamond),
phosphatases (triangle), transcription regulators (horizontal ellipse), translation regulators (hexagon), transmembrane receptors (vertical ellipse),
transporters (trapezoid), microRNA (inverted trapezoid), complexes (thick circle), and other important molecules (circle). Dotted lines indicate an
indirect interaction, while solid lines indicate a direct interaction.
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Page 5 of 9literature. Several AEDs that actually do inhibit aroma-
tase - lamotrigine (DB #555), oxcarbazepine (DB #776),
tiagabine (#906), phenobarbital (DB #1174), and phe-
nytoin (DB #252) - were identified through this
method, whether by the TGT or by the Eshape3D fin-
gerprint type. These compounds, as well as the five
proposed by the similarity search method, are shown
in Additional file 4: Table S4 to further highlight their
structural similarity.
In fact, the only aromatase-inhibiting AEDs not picked
up through the similarity analyses - but still hit by the
Merged Model - are ethosuximide (DB #593) and

Zalcitabine 
(DB #943) 
Triamterene 
(DB #384)
  Voriconazole 
(DB #582)
 
Metyrapone 
(DB #1011) 
Leflunomide 
(DB #1097) 
Zaleplon 
(DB #962)
 
Dasatinib 
(DB #1254)
 
Atropine 
(DB #572) 
Scopolamine 
(DB #747)
 
Fluoxymesterone 
(DB #1185) 
Adefovir Dipivoxil 
(DB #718) 
Figure 3 Diagrams depicting multiple target interactions of the potential AEDs proposed by the Merged pharmacophore model
search. These compounds were chosen from among the set of molecules in Additional file 5: Table S5 for their structural diversity and oral-
availability. Specific molecule types are represented as indicated in Figure 2 legend.
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Page 6 of 9valproic acid (DB #313). Valproic acid, with a structure
rather unlike other aromatase-inhibiting AEDs, is likely
to bind differently to the aromatase active site. As a
result, it may be considered as irrelevant to the similar-
ity analyses. Ethosuximide, on the other hand, does clo-
sely resemble the chemical structures of some of the
other aromatase-inhibiting AEDs identified through the
similarity analyses but was not similar enough to the
top five AIs to be identified at 70% overlap.
Regardless, the similarity search method did, in gen-
eral, hit several compounds that are both AIs as well as
AEDs. More importantly, however, these analyses speak
to the relative similarity between potent AIs and current
antiepileptic drugs. In addition, it has become apparent
that a pharmacophore search with a model - originally
designed to find new classes of AIs - could also yield
potential new AEDs that are less toxic and more toler-
able. The pharmacophore search of the FDA-approved
set of compounds from the DrugBank offers some
potential leads for accomplishing this. In Additional file
5: Table S5 are reported the compounds that were hit
by the Merged Model with a very low RMSD value, less
than or equal to 0.20 Å. As shown here, already FDA-
approved treatments offer potential for inhibiting aro-
matase. It is noted that, in fact, Lamotrigine (DB #555),
a current antiepileptic drug that was also proposed for
aromatase inhibition through the similarity analyses,
falls in the set of Merged Model hits with RMSD less
than or equal to 0.20 Å, as well.
Interactions between the seven aromatase-inhibiting
AEDs in Additional file 2: Table S2 and multiple targets
were obtained through the IPA analysis [27]. Diagrams
depicting these interactions [27] are shown in Figure 2
for six of the seven aromatase inhibiting AEDs (informa-
tion about the interactions of oxcarbazepine (DB #776)
was unavailable). Interactions [27] of the structurally-
diverse and orally-available compounds among the pro-
p o s e dA E D sf r o mA d d i t i o n a lf i l e5 :Table S5 were also
obtained, and these are depicted below in Figure 3.
These compounds were chosen specifically for their
diverse structural characteristics and their oral availabil-
ity as therapeutic agents.
Additionally, the interaction information was compiled
into Additional file 6 &7: Table S6 and S7 so that a
breakdown of these interactions for each compound could
be obtained. For example, Additional file 6: Table S6
shows the number of specific types of proteins - such as
cytokines, enzymes, kinases, etc. - on which each aroma-
tase-inhibiting AED has an influence. Additional file 7:
Table S7 shows the same for the proposed AEDs from
Additional file 5: Table S5. In general, the compounds
with relatively fewer off-target effects offer the most pro-
mise for developing less toxic, more tolerable AEDs; there-
fore, it can be seen that some of the compounds in the set
of FDA-approved drugs that were hit by the Merged phar-
macophore model with an RMSD value less than or equal
to 0.20 Å do, indeed, show some potential.
Conclusions
All in all, this study has shown that a pharmacophore
model [18] - originally derived from potent AIs and from
the aromatase active site structure - can be used to screen
for AEDs. The screening of the FDA-approved subset of
compounds from the DrugBank [22,23] with the Merged
Model [18] returned 45 compounds with RMSD less than
or equal to 0.20 Å that offer promise as potential AEDs.
Through this study, the similarity between AIs and AEDs,
with regard to both structure and chemical features, has
also been shown. In fact, through these analyses, several
AIs with significant similarity (over 70%) with some of the
top five AIs were identified as having potential for aroma-
tase-inhibition, as well.
The most important conclusions from this study are
that: (1) a very good percentage of AEDs (73%) and of
anticonvulsant compounds (82%) fit the pharmacophore
model originally generated to screen for different classes
of AIs, and (2) since several AEDs are also very similar
to several AIs - specifically, the top five - this pharmaco-
phore model can be used to find less toxic, more toler-
able AEDs.
Additionally, it can be argued that the chemical and
structural similarity of these two sets of compounds
hints at the potentially significant role of aromatase in
epilepsy. These findings offer leads into prospective new
strategies for epilepsy treatment, made especially valu-
able given the challenges involved in treating this condi-
tion. For example, it is known that 30% of the newly
diagnosed patients do not respond sufficiently to mono-
therapy [5]. Therefore, compounds capable of inhibiting
aromatase should be investigated for potential in poly-
therapy, based on mechanism of action, in addition to
being tested for antiepileptic properties. Specifically,
with regard to men with epilepsy, current clinical data
suggests that aromatase inhibitors could possibly
enhance patient responses to antiepileptic treatments
and that compounds capable of inhibiting aromatase
should be analyzed for potential use in antiepileptic
treatments [7]. Additionally,t o x i c i t yi s s u e sa n da d v e r s e
side effects incurred with the current treatment options
for epilepsy can be avoided through the design of new,
less harmful drugs for antiepileptic therapy. It has been
clinically determined through recent studies that, at
least in the short term, men who are prescribed aroma-
tase inhibitors for conditions that stem from hormonal
imbalances do not show signs of bone thinning or loss
of bone density [10]. In that sense, inhibitors of the
human aromatase enzyme seem to have great potential
for use in antiepileptic treatments.
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proposed for potential aromatase inhibition, as shown in
Additional file 4: Table S4, should be assayed in vivo.T h e
potential AEDs shown in Additional file 5: Table S5 -
with the exception of Lamotrigine (DB #555) - are clear
examples of compounds that could be assayed both for
aromatase inhibition and for anticonvulsant properties, as
well. In addition, the Merged Model generated in previous
work [18] can be used to screen databases other than the
FDA-approved set of compounds analyzed in this study.
In this way, less toxic and more tolerable AEDs could be
identified for the treatment of epilepsy.
Additional material
Additional file 1: Top five aromatase inhibitors. Top five AIs identified
as having lowest RMSD values from the Merged pharmacophore model
generated and explained in previous work [18][file cites [4,6,30-34]].
Additional file 2: Aromatase-inhibiting AEDs hit by the Merged
Model. Seven out of seven aromatase-inhibiting antiepileptic drugs [5]
hit by the Merged pharmacophore model [18].
Additional file 3: Results of similarity analyses AEDs hit by the
Merged Model. Results of similarity analyses performed on the set of
AEDs hit by the Merged pharmacophore model [18]. Compounds that
were found similar to one of the top five AIs at an overlap value of at
least 70% by both fingerprint methods are reported in bolded text.
Additional file 4: Aromatase-inhibiting AEDs identified and AEDs
proposed to be aromatase-inhibiting by similarity analyses.
Aromatase-inhibiting antiepileptic drugs identified by similarity analyses
and AEDs proposed to be aromatase-inhibiting through similarity
analyses.
Additional file 5: FDA-approved Hits with RMSD less than or equal
to 0.20 Å. FDA-approved Merged pharmacophore model [18] hits with
RMSD less than or equal to 0.20 Å
Additional file 6: Breakdown of the protein interactions of the
aromatase-inhibiting AEDs. Protein interactions of the aromatase-
inhibiting AEDs broken down into specific types of proteins as indicated
in Figure 2 legend.
Additional file 7: Breakdown of the protein interactions of the
proposed AEDs. Protein interactions of the proposed AEDs from
Additional file 5: Table S5 broken down into specific types of proteins as
indicated in Figure 2 legend.
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